Here are five things to know:
1. Cartiva develops technology to treat osteoarthritis, cartilage damage and musculoskeletal conditions.
2. Cartiva’s synthetic cartilage implant, which is designed to treat osteoarthritis at the base of the big toe, earned premarket approval in July 2016.
3. Consisting of biocompatible, durable and low-friction organic polymer, the cartilage implant functions like natural cartilage and can be implanted in close to 35 minutes.
4. In addition to the U.S., Cartiva secured regulatory approvals for the implant in Canada, Europe, Brazil, Chile and Australia.
5. The deal will provide Wright Medical with PM-approved technology for a high-volume foot and ankle procedure.
The deal is expected to finalize in the fourth quarter.
More articles on devices:
OrthoSensor raises $2.5M: 3 notes
FDA issues warning letter to Zimmer Biomet on Warsaw North Campus violations: 6 things to know
3 things to know about Xtant Medical CEO Carl O’Connell
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
